Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/nfe2l2-sXVHCXj0Cy
References (26)
-
T. Rushmore, A. Kong (2002)
Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.Current drug metabolism, 3 5
-
Yasuda (1998)
On behalf of the Japanese Association for Thoracic Surgery: thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese association for thoracic surgeryJpn J Cardiothorac Surg, 48
-
N. Reddy, S. Kleeberger, Masayuki Yamamoto, T. Kensler, Catherine Scollick, S. Biswal, S. Reddy (2007)
Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection.Physiological genomics, 32 1
-
Jeong‐Min Cho, Sarala Manandhar, Hyang-Rim Lee, Hyun-Min Park, M. Kwak (2008)
Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.Cancer letters, 260 1-2
-
T. Arisawa, T. Tahara, T. Shibata, M. Nagasaka, Masakatsu Nakamura, Y. Kamiya, H. Fujita, D. Yoshioka, M. Okubo, I. Hirata, H. Nakano (2008)
Nrf2 gene promoter polymorphism and gastric carcinogenesis.Hepato-gastroenterology, 55 82-83
-
K. Yasuda, H. Ayabe, H. Ide, Y. Uchida (2000)
Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery. Committee of Science.The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 48 6
-
S. Homma, Yukio Ishii, Y. Morishima, Tadahiro Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, Masayuki Yamamoto (2009)
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung CancerClinical Cancer Research, 15
-
T. Shibata, T. Ohta, K. Tong, A. Kokubu, Reiko Odogawa, K. Tsuta, H. Asamura, Masayuki Yamamoto, S. Hirohashi (2008)
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancyProceedings of the National Academy of Sciences, 105
-
Taiana Ja, Aracama Va, E. Schieppati (1952)
[Cancer of the lung].The Journal of the International College of Surgeons, 17 4
-
Truyen Nguyen, Chung Yang, C. Pickett (2004)
The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress.Free radical biology & medicine, 37 4
-
G. Semenza (2003)
Targeting HIF-1 for cancer therapyNature Reviews Cancer, 3
-
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
-
J. Fahey, T. Kensler (2007)
Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes.Chemical research in toxicology, 20 4
-
H. Sasaki, S. Shimizu, K. Endo, M. Takada, M. Kawahara, Hisaichi Tanaka, A. Matsumura, K. Iuchi, H. Haneda, E. Suzuki, Y. Kobayashi, M. Yano, Y. Fujii (2006)
EGFR and erbB2 mutation status in Japanese lung cancer patientsInternational Journal of Cancer, 118
-
Jie Zhou, T. Schmid, S. Schnitzer, B. Brüne (2006)
Tumor hypoxia and cancer progression.Cancer letters, 237 1
-
K. Endo, A. Konishi, H. Sasaki, M. Takada, Hisaichi Tanaka, M. Okumura, M. Kawahara, H. Sugiura, Y. Kuwabara, I. Fukai, A. Matsumura, M. Yano, Y. Kobayashi, K. Mizuno, H. Haneda, E. Suzuki, K. Iuchi, Y. Fujii (2005)
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.Lung cancer, 50 3
-
S. Papaiahgari, Adi Yerrapureddy, P. Hassoun, Joe Garcia, K. Birukov, S. Reddy (2007)
EGFR-activated signaling and actin remodeling regulate cyclic stretch-induced NRF2-ARE activation.American journal of respiratory cell and molecular biology, 36 3
-
(1998)
On behalf of the Japanese Association for Thoracic Surgery: thoracic and cardiovascular surgery in Japan -
Y. Kim, J. Ahn, P. Liang, C. Ip, Yuesheng Zhang, Young-Mee Park (2007)
Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.Cancer research, 67 2
-
Anju Singh, Swetlana Boldin-Adamsky, R. Thimmulappa, S. Rath, H. Ashush, J. Coulter, A. Blackford, S. Goodman, F. Bunz, W. Watson, E. Gabrielson, E. Feinstein, S. Biswal (2008)
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.Cancer research, 68 19
-
T. Kensler, N. Wakabayashi, S. Biswal (2007)
Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway.Annual review of pharmacology and toxicology, 47
-
S. Papaiahgari, Qin Zhang, S. Kleeberger, Hye-Youn Cho, S. Reddy (2006)
Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells.Antioxidants & redox signaling, 8 1-2
-
K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, Kazuhiko Igarashi, J. Engel, J. Engel, Masayuki Yamamoto (1999)
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.Genes & development, 13 1
-
H. Sasaki, K. Endo, A. Konishi, M. Takada, M. Kawahara, K. Iuchi, A. Matsumura, M. Okumura, Hisaichi Tanaka, T. Kawaguchi, Toshiki Shimizu, H. Takeuchi, M. Yano, I. Fukai, Y. Fujii (2005)
EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCyclerClinical Cancer Research, 11
-
P.E. Baldry, B. Golberg, E. Moyes, P.G. Arblaster, P.F. Jones, T.M. Wilson, R. Grenville-Mathers, H. Trenchard, D. Paradise (1960)
Bronchial CarcinomaInternational Journal of Clinical Practice, 14
-
K. Itoh, T. Chiba, Satoru Takahashi, T. Ishii, Kazuhiko Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, Masayuki Yamamoto, Y. Nabeshima (1997)
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.Biochemical and biophysical research communications, 236 2
- ISSN
- 1556-0864
- DOI
- 10.1097/JTO.0b013e3181db3dd3
- pmid
- 20421815
- Publisher site
- See Article on Publisher Site
Abstract
ORIGINAL ARTICLE NFE2L2 Gene Mutation in Male Japanese Squamous Cell Carcinoma of the Lung Hidefumi Sasaki, MD, PhD, Yu Hikosaka, MD, PhD, Katsuhiro Okuda, MD, PhD, Osamu Kawano, MD, PhD, Satoru Moriyama, MD, PhD, Motoki Yano, MD, PhD, and Yoshitaka Fujii, MD, PhD The nuclear factor (erythroid derived 2)- like 2 Introduction: Recently, the nuclear factor (erythroid derived 2)-like (NFE2L2) is a master transcriptional activator of genes en- 2(NFE2L2) gene mutations were identified in lung cancer. The coding many cytoprotective enzymes that are induced in constitutive activation of NFE2L2 in lung cancer cells promotes response to environmental and endogenously derived oxida- tumorigenicity. However, the correlation between NFE2L2 mutation 3–5 tive/electrophilic agents. In normal cells, NFE2L2 is a cap status and clinicopathologic features of lung cancer has not been ‘n’ collar basic leucine zipper transcription factor. NFE2L2- well characterized. deficient mice are highly susceptible to chemically induced Methods: We have investigated NFE2L2 gene mutation status in 6,7 carcinogenesis of multiple organs. A previous report 263 surgically treated lung cancer cases at Nagoya City University showed that RNAi-mediated silencing of NFE2L2 gene ex- Hospital. The NFE2L2 mutation was analyzed by direct sequencing pression in non-small cell lung cancer inhibited tumor of
Journal
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jun 1, 2010